Access to drugs for treating hepatitis C in Russia in 2013

The purpose of this report was to investigate the situation regarding access to drugs treating the hepatitis C virus (HCV) in Russia. To this end, Treatment Preparedness Coalition made an overview of the applicable legislation, and likewise analyzed the data relating to governmental drug procurements, statistics on the prevalence and incidence of hepatitis C in various territories of the Russian Federation, and data regarding the financing of HCV treatment programs.

The relevance of this report is above all due to the extent of the epidemic in Russia. The number of people with HCV in Russia falls within the range of a few hundred thousand people (official data) to several million (estimated). Accurate statistics are not available due to the lack of a unified system for collecting and analyzing data related to the HCV epidemic on the federal level.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.